AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Johnson & Johnson: Morgan Stanley maintains a 'Equal-Weight' Rating, The Target Price is $171
ByAinvest
Thursday, Jul 10, 2025 2:00 pm ET1min read
Morgan Stanley maintains 'Equal-Weight' rating on Johnson & Johnson(JNJ).
The target price is $171, compare with $169 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-10 | Morgan Stanley | Maintains | Equal-Weight | Equal-Weight | $171 | $169 |
[Company Profile] Johnson & Johnson was incorporated in the State of New Jersey in 1887. Johnson & Johnson and its subsidiaries have engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. The Company is organized into two business segments: Innovative Medicine and MedTech.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet